A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports this week in Science Translational Medicine. The findings support further development of the drug candidate for treating and preventing current coronavirus infections and potential future epidemic outbreaks.
Coronaviruses are a genetically diverse family of viruses that infect birds and mammals, with most coronavirus strains limited to infecting only certain hosts. Human coronaviruses, for example, cause up to 30 percent of common colds.
In the last 15 years, however, coronaviruses have demonstrated their ability to jump into new species. Zoonotic (animal) coronaviruses have infected humans, causing severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), severe diseases with high mortality rates ranging from 10 percent for SARS to 40 percent for MERS. The MERS-coronavirus continues to cause new infections in the Middle East.
“There’s a real concern that the MERS coronavirus could escape broadly when millions of people visit Saudi Arabia for the Hajj,” said Mark Denison, M.D., Craig-Weaver Professor of Pediatrics and professor of Pathology, Microbiology and Immunology at Vanderbilt University School of Medicine.
But to date, there has been no effective antiviral drug for any known coronavirus, Denison noted.
Denison and his team at Vanderbilt have studied the basic biology of coronaviruses for more than 20 years. In an effort to find chemical tools that would allow them to probe viral replication, graduate student Brett Case screened a series of compounds selected and provided by Gilead Sciences.
Case demonstrated that one of the compounds was highly active against coronaviruses in cultured cells. The finding was a surprise, Denison said, because compounds in the same class (nucleoside analogs) have normally failed to inhibit coronavirus replication.
The compound, called GS-5734, is currently in clinical development for treatment of Ebola virus disease.
Denison’s longtime collaborator Ralph Baric, Ph.D., at the University of North Carolina and his team demonstrated that GS-5734 inhibits SARS-coronavirus and MERS-coronavirus replication in multiple in vitro systems, including cultures of primary human airway epithelial cells, which are the cells infected by respiratory coronaviruses.
The researchers also showed that GS-5734 was effective against a circulating human coronavirus, bat coronaviruses, and bat coronaviruses that are considered “prepandemic” because they can infect cultured human cells.
Using a mouse model of SARS, the investigators demonstrated that both prophylactic (before infection) and early therapeutic (soon after infection) administration of GS-5734 reduced viral load in the lungs and improved respiratory functions.
“This compound shows broad activity against a variety of human and animal coronaviruses and represents an exciting potential therapeutic for a family of viruses prone to emergence from animal reservoirs,” Denison said.
Denison and his team at Vanderbilt will continue to use the compound “as a probe to try to understand the biology of the virus, how and why this drug works, and to identify new targets for inhibiting coronaviruses,” he said.
“This is an exciting example of how pursuing fundamental research to understand the mechanisms of virus replication and pathogenesis can lead to an important compound with therapeutic potential.”
The Latest on: Coronaviruses
- Coronavirus warning issued after multiple infected people attend N.C. funeralon August 7, 2020 at 5:20 am
"The positive test results came after the events, though others who were in attendance may have been exposed to the virus," a notice from the Chatham County health department said.
- COVID-19 deaths in U.S. surpass 160K amid another 60,000 caseson August 7, 2020 at 5:20 am
The COVID-19 death toll in the United States has surpassed 160,000, updated scientific research data showed Friday.
- Cuomo expected to announce New York's school reopening plan amid coronavirus pandemicon August 7, 2020 at 5:09 am
New York Gov. Andrew Cuomo is slated to announce Friday whether the state’s public schools will reopen this fall amid the coronavirus pandemic, while noting that the final decision is not his alone.
- Five months on, and EU health workers can’t bear to contemplate a second Covid-19 waveon August 7, 2020 at 5:00 am
When the Guardian spoke to staff in March they had no time for reflection. So what do they think of the new surge now?
- How California is preparing for in-person voting this year due to coronaviruson August 7, 2020 at 5:00 am
California elections officials are scrambling to determine how many voting locations they can muster, and how they'll find enough short-term workers to enforce coronavirus safety measures.
- Second stimulus check updates: Sides ‘still very far apart’ as coronavirus relief talks in danger of collapseon August 7, 2020 at 4:59 am
Washington talks on vital COVID-19 rescue money are teetering on the brink of collapse after a marathon meeting in the Capitol.
- 2nd, deeper test says Ohio Gov. Mike DeWine doesn't have COVID-19on August 7, 2020 at 4:58 am
A second, more sensitive test has shown that Ohio Gov. Mike DeWine does not have COVID-19, his office said. DeWine initially tested positive on Thursday during normal protocol required to meet ...
- Eye Opener: Model predicts nearly 300,000 U.S. COVID-19 deaths by Decemberon August 7, 2020 at 4:57 am
A new model predicts U.S. coronavirus deaths will reach nearly 300,000 by December 1. Also, New York Attorney General Letitia James filed a lawsuit seeking to dissolve the National Rifle Association.
- 3 DNC workers test positive for COVID-19 after screeningon August 7, 2020 at 4:53 am
Three workers hired to help set up the Democratic National Convention in Milwaukee have tested positive for COVID-19, according to the event's organizers. Daily ...
- One in three Americans say they would not get coronavirus vaccine: pollon August 7, 2020 at 4:48 am
Thirty-five percent of Americans say that they would not get a free, FDA-approved vaccine for COVID-19 according to a new Gallup poll.
via Google News and Bing News